NEW YORK (AP) — Novartis said Thursday the FDA approved Valturna to treat high blood pressure. The drug is a single-pill combination of valsartan and aliskiren. Valsartan is the active ingredient in Novartis’ high blood pressure drug Diovan while aliskiren is the active ingredient in the company’s blood pressure drug Tekturna. Shares of Switzerland-based Novartis fell 40 cents to close at $48.20.
